Calibrate
Metabolic reset combining prescribing with intensive one-to-one coaching
Founded 2019 · New York, NY · Private · Website
Our verdict
A strong member experience wrapped around misaligned incentives. Buy only if you have already solved cost control elsewhere and are buying clinical quality — and insist on intent-to-treat numbers before signing.
Scorecard
How it scored
Scored against the published rubric. Weights are fixed before review and identical for every vendor.
Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.
Quality of published results: peer review, sample size, control group, and follow-up duration.
Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.
Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.
PBM, carrier, HRIS, and point-solution interoperability without custom engineering.
Time to first appointment, app quality, care-team continuity, and support responsiveness.
Analysis
What we found
Calibrate delivers a legitimately high-touch clinical experience, and members like it — the satisfaction and retention numbers are among the best in this set. The difficulty is financial. Its economics improve when more members start and stay on medication, which is precisely the opposite of what a self-insured CFO needs from a GLP-1 strategy. Reported outcomes are also completer-weighted, and the gap between completer and intent-to-treat results in this category is routinely large enough to change a purchasing decision.
Strengths
- Genuinely intensive clinical model — quarterly physician visits are well above the market norm
- Coaching relationship is one-to-one and continuous rather than pooled, which shows up in retention
- Shortest contract term in the full-service tier, so a pilot is realistically reversible
Limitations
- Completer-based outcome reporting overstates real-world results; ask for intent-to-treat
- Cost control is weak — the model is designed to start members on therapy, not to triage them off it
- Reporting depth lags the enterprise-grade vendors and requires manual work from your team
Best for
Mid-market employers who want a turnkey clinical program and are willing to accept drug trend in exchange for speed.
Watch out
The weight-loss guarantee excludes pharmacy spend entirely. It protects the program fee, not your budget.
The details
Commercial and clinical specifics
The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.
Pricing
- Model
- Per-participant program fee, billed annually
- PMPM range
- $65–$110
- Setup fee
- Typically $10k–25k implementation
- Medications included
- No
- Performance guarantees
- Weight-loss guarantee with partial refund; drug spend explicitly excluded
Contract
- Minimum lives
- 500
- Term
- 12 months
- Termination notice
- 60 days
Eligibility
- BMI threshold
- BMI ≥ 30, or ≥ 27 with comorbidity
- Prior authorization
- Yes
- Step therapy
- No
- Comorbidity required
- No
Clinical model
- Prescribes
- Yes
- Care team
- Board-certified physicians, Nurse practitioners, Accountability coaches
- Titration protocol
- Physician-directed titration with mandatory quarterly video visits and lab monitoring
- Off-ramp
- One-year maintenance curriculum after target weight, coach-led
- Formulary
- Semaglutide, Tirzepatide, Liraglutide, Metformin adjunct
Outcomes evidence
- Headline claim
- 16.2% average weight loss at 12 months and 17.9% at 24 months, from a company Results Report certified by the Validation Institute
- Evidence level
- White paperVendor-authored, methodology disclosed but not independently reviewed.
- Sample size
- More than 16,000 members in the certified report
- Follow-up
- 12 and 24 months, with 36-month figures claimed on its own site
Sources
- Validation Institute certifies Calibrate's Results Report16.2% at 12 months and 17.9% at 24 months across 16,000+ members
- Calibrate: how the Metabolic Reset worksCompany claims 16% at 12 months, 18% at 24 and 20% at 36
Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.
Integrations
- PBMs
- CVS Caremark, Express Scripts
- Carriers
- Aetna, Cigna
- HRIS
- Workday, ADP
- Eligibility file
- Flat file, monthly cadence
Formulary
Calibrate by medication
How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
Calibrate Reviews Semaglutide
GLP-1 receptor agonist
A first-line option with no required lower-cost trial. Physician-directed titration with quarterly video visits and lab monitoring is genuinely above the market norm for clinical intensity.
Calibrate Reviews Tirzepatide
Dual GIP/GLP-1 receptor agonist
Treated interchangeably with semaglutide as a first-line choice, selected on tolerability and coverage rather than on a cost hierarchy. The quarterly physician cadence carries across.
Calibrate Reviews Liraglutide
GLP-1 receptor agonist
Available but rarely the starting point. In practice it appears where the weekly agents are contraindicated or unavailable rather than as a deliberate cost step.
Calibrate Reviews Metformin
Biguanide
Used alongside incretin therapy for members with glycemic indications rather than as a standalone weight intervention or a required first rung.
Alternatives
Others in full-service clinical
Same category, so these are genuine substitutes rather than different products at different prices.
Board-certified obesity medicine delivered virtually
- PMPM benchmark
- $58–$105
- Minimum lives
- 500
Personalized weight care spanning medication, behavior, and biology
- PMPM benchmark
- $45–$85
- Minimum lives
- 500
Combined cardiometabolic and mental health care in one care team
- PMPM benchmark
- $38–$78
- Minimum lives
- 1,000